UPDATE: BMO Capital Upgrades ARIAD (ARIA) to Outperform; Assets Likely to Attract M&A Interest

January 24, 2014 11:26 AM EST Send to a Friend
Get Alerts ARIA Hot Sheet
Price: $6.52 -0.76%

Rating Summary:
    10 Buy, 12 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade ARIA Now!
Join SI Premium – FREE
(Updated - January 24, 2014 12:01 PM EST)

BMO Capital upgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Market Perform to Outperform with a price target of $14.00 (from $8.00). Analyst Jim Birchenough sees significant value in the company's assets and he believes it will attract interest from large pharma.

The recent stock advance is tied to reports from Daily Mail about a possible takeover. ARIAD acknowledged to BMO that all options, including partnerships and M&A, remain on the table, as indicated previously.

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $7.52 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Hot Upgrades, Upgrades

Related Entities

BMO Capital

Add Your Comment